Secretome Therapeutics: Pioneering nCPC-Based Cardiovascular Therapies
  • Home
  • Pipeline
  • Leadership
  • News & Publications
    • News
    • Publications
Select Page

Characterization and Functionality of Cardiac Progenitor Cells in Congenital Heart Patients

by Sudhish Sharma | Feb 1, 2011 | Journals, Uncategorized

Abstract Background—Human cardiac progenitor cells (hCPCs) may promote myocardial regenerationin adult ischemic myocardium. The regenerative capacity of hCPCs in young patients withnonischemic congenital heart defects for potential use in congenital heart defect...
Next Entries »

Recent Posts

  • Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction
  • Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
  • Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
  • Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
  • Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21
© 2025 Secretome Therapeutics | Brady UX